๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

1246 POSTER Phase II study of Gemcitabine in children with solid tumors of mesenchymal and embryonal origin

Book ID
122735615
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
142 KB
Volume
3
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of daily oral etoposide i
Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors
โœ Needle, Michael N.; Molloy, Patricia T.; Geyer, J. Russell; Herman-Liu, Alisa; B ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 315 KB ๐Ÿ‘ 2 views

Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of or

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
โœ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and